Cellectar Biosciences, Inc. - Common Shares (CLRB)

CUSIP: 15117F500

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class
Equity / Common Shares
Shares outstanding
4,503,909
Total 13F shares
3,006,006
Share change
+1,539,765
Total reported value
$3,849,000
Price per share
$1.28
Number of holders
21
Value change
+$1,971,582
Number of buys
13
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 15117F500?
CUSIP 15117F500 identifies CLRB - Cellectar Biosciences, Inc. - Common Shares in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of CLRB - Cellectar Biosciences, Inc. - Common Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Boxer Capital, LLC
13F
Company
20%
920,000
$1,226,000 31 Mar 2020
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
5.2%
232,102
$309,000 31 Mar 2020
13F
SPHERA FUNDS MANAGEMENT LTD.
13F
Company
1.9%
87,500
$111,000 31 Mar 2020
13F
FNY Investment Advisers, LLC
13F
Company
1.5%
69,600
$88,000 31 Mar 2020
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
1.2%
55,869
$71,000 31 Mar 2020
13F
Game Plan Financial Advisors, LLC
13F
Company
0.88%
39,624
$51,000 31 Mar 2020
13F
VANGUARD GROUP INC
13F
Company
0.37%
16,755
$22,000 31 Mar 2020
13F
MORGAN STANLEY
13F
Company
0.27%
12,221
$16,000 31 Mar 2020
13F
CITADEL ADVISORS LLC
13F
Company
0.27%
12,155
$15,000 31 Mar 2020
13F
PNC FINANCIAL SERVICES GROUP, INC.
13F
Company
0.22%
10,000
$13,000 31 Mar 2020
13F
WELLS FARGO & COMPANY/MN
13F
Company
0.09%
4,000
$5,000 31 Mar 2020
13F
US BANCORP \DE\
13F
Company
0.06%
2,857
$4,000 31 Mar 2020
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.03%
1,490
$2,000 31 Mar 2020
13F
VICTORY CAPITAL MANAGEMENT INC
13F
Company
0.03%
1,465
$2,000 31 Mar 2020
13F
UBS Group AG
13F
Company
0.01%
603
$1,000 31 Mar 2020
13F

Institutional Holders of Cellectar Biosciences, Inc. - Common Shares (CLRB) as of Q2 2020

As of 30 Jun 2020, Cellectar Biosciences, Inc. - Common Shares (CLRB) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,006,006 shares. The largest 10 holders included BOXER CAPITAL, LLC, RENAISSANCE TECHNOLOGIES LLC, Worth Venture Partners, LLC, Sio Capital Management, LLC, CVI Holdings, LLC, Quilter Plc, FNY Investment Advisers, LLC, SPHERA FUNDS MANAGEMENT LTD., TWO SIGMA ADVISERS, LP, and WEDBUSH SECURITIES INC. This page lists 21 institutional shareholders reporting positions in this security for the Q2 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2020 vs Q1 2020 Across Filers

Q1 2020 holders
15
Q2 2020 holders
21
Holder diff
6
Investor Q1 2020 Shares Q2 2020 Shares Share Diff Share Chg % Q1 2020 Value $ Q2 2020 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .